Drugs / Omicron Variant RBD-based ARVAC-CG vaccine
Omicron Variant RBD-based ARVAC-CG vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05752201 | Feb → Aug 2023 | — | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omicron Variant RBD-based ARVAC-CG vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05752201 ↗ |
| Modality | Vaccine | “recombinant booster vaccine (ARVAC)” PMID 40179522 ↗ Apr 2025 |
| Route | Intramuscular | “Administration route: intramuscular (IM) injection” NCT05752201 ↗ |